Respecting your elders: osimertinib demonstrates preferential activity in elderly patients with T790M positive non-small cell lung cancers

Ever since Lynch et al. identified that some non-small cell lung cancers (NSCLCs) responded to the EGFR inhibitors gefitinib and erlotinib, and this could be correlated to activating mutations in EGFR, one of the great success stories in the era of targeted therapies was born.